Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.
It was not until 2018 that the US FDA approved the first therapy developed using the technique. Since then, there’s been a steady, but slow, number of RNAi treatments coming into the market. The ROBO ...
-- Novel approach to gene knockdown uses proprietary CASi (Conditionally Activated siRNA) molecules optimized to “switch” on, activating siRNA therapeutics only in selected cells -- -- CASi platform, ...
RNA interference (RNAi) therapy offers groundbreaking potential to revolutionize disease treatment by targeting gene silencing. Opportunities lie in developing alternative treatments for conditions ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ...
Morning Overview on MSN
RNA strand that nearly self-replicates could unlock life’s origin
A 45-nucleotide strand of RNA can now synthesize both its mirror-image complement and a copy of itself, bringing scientists ...
Researchers engineered RNA micelles carrying gemcitabine, survivin-targeting siRNA and a tumor-binding ligand. In mice with ...
University of Queensland research has revealed that double-stranded RNA-based biopesticides (dsRNA) sprayed on plant leaves ...
When a neuron in our body gets damaged, segments of RNA produce proteins that can help repair the injury. But in neurological disorders such as ALS and spinal muscular atrophy, or following spinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results